PRA Health Sciences (PRAH) Tops Q4 EPS by 10c, FY EPS Guidance Tops Views

PRA Health Sciences (NASDAQ: PRAH) reported Q4 EPS of $0.59, $0.10 better than the analyst estimate of $0.49. Revenue for the quarter came in at $428.9 million versus the consensus estimate of $353.42 million.

GUIDANCE:

PRA Health Sciences sees FY2016 EPS of $2.32-$2.42, versus the consensus of $2.19.

For earnings history and earnings-related data on PRA Health Sciences (PRAH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance